Jump to content

rene in geneva

Member
  • Posts

    191
  • Joined

  • Last visited

Everything posted by rene in geneva

  1. rene in geneva

    AAH

    Anyone paying attention today? http://www.sharescene.com/html/emoticons/biggrin.gif
  2. rene in geneva

    AAH

    Anyone paying attention today? http://www.sharescene.com/html/emoticons/biggrin.gif
  3. A good ally against the dogma driven green hoards....... tim flannery- nuclear the only practical way cheers, Rene
  4. Spot on Early Bird.. zenyth takover
  5. Trading halt.............are we finally going to see something from this sleepy fellow? http://www.sharescene.com/html/emoticons/unsure.gif
  6. Rodents love the story...... Ferret news
  7. Good article in The Age today. Not mentioning the Silex name, but just more comment on the nuclear issue and the perpetual 12% income stream for making nuclear fuel cheaper. Nuclear Power debate
  8. Things to learn before you travel......... My Webpage http://www.sharescene.com/html/emoticons/lmaosmiley.gif
  9. More news.......... silex news http://www.sharescene.com/html/emoticons/biggrin.gif
  10. Part of GE's announcement: "By acquiring the exclusive rights to complete the process development and commercial deployment of Silex's enrichment technology, GE will be in a strong position to support anticipated demands for enriched uranium," said Andy White, president and CEO ofGE's nuclear business. "GE is very excited about the transaction and the potential ofthis innovative technology. We are looking forward to the completionof its development and bringing this product to the global marketplace," White added. "By adding the next generation of enrichment technology to itsnuclear portfolio, GE has the potential to offer the most efficientenrichment technology available to a range of existing commercialcustomers and businesses," White said.
  11. Lunch time presentation in Sydney to explain the agreement. Lets see if it strikes the right note. http://www.sharescene.com/html/emoticons/wink.gif
  12. rene in geneva

    AAH

    Domantis Based: Waltham, MA and Cambridge, U.K. Founded: 2000 www.domantis.com Why It's Fierce: A love for the game helps, and Domantis CEO Robert Connelly clearly loves a start-up. He first got the bug when Abbott assigned him to integrate a new acquisition into the "Abbott beast." He's been able to give free rein to his entrepreneurial side at Domantis, where he was brought in to get the brainchild of two prominent U.K. scientists--Gregory Winter and Ian Tomlinson--up and running. Winter was one of the early pioneers of antibody engineering and was a co-founder of Cambridge Antibody Technology. Tomlinson was deputy director of the Medical Research Council's Centre for Protein Engineering in Cambridge and is now Domantis' chief scientific officer in the U.K.-based lab. Connelly focuses on the business side of the operations in Waltham. Within the first two years of launching, Domantis had a dozen programs up and running for chronic obstructive pulmonary disease, rheumatoid arthritis, asthma, colorectal cancer and more . At the heart of its work lies human domain antibodies, or dAbs. One of their dAbs can neutralize cytokine receptor targets. Others have dual targeting characteristics, with one molecule binding to two therapeutic targets. One of the reasons why dAbs are so attractive as a therapeutic, says Connelly, is that they are very stable and soluble, suitable for being administered either orally or as an injectable. "It's always been about dAbs," says Connelly. "Dual targeting is one of the really unique things you can do with dabs." Domantis has inked therapeutic partnerships with Argenta Discovery, Tanox and Peptech. But it was the deal with Bristol-Myers Squibb late last year that helped focus new attention on the development group. The two companies signed a pact to develop a range of dAbs for T-cell co-stimulation, which is part of the human immune response. Domantis pocketed more than $9 million up front and stands to gain up to $20 million in milestones for each new product developed. Near the end of last year, Domantis announced a new round of $29 million in venture funds, with a chunk of the money coming from Novo Nordisk. The company has raised $83 million in venture capital so far. What to look for: Domantis plans to ramp up two to three new INDs a year, starting next year. After that, says Connelly, the company has to decide whether it advances new programs past proof-of-concept on its own or licenses them out. But expect a licensing deal for Domantis' asthma program in a matter of months.
  13. rene in geneva

    AAH

    Shhh! Don't say a word everyone, the traders might be watching http://www.sharescene.com/html/emoticons/icon13.gif
  14. rene in geneva

    AVX

    In reply to: turbo on Wednesday 09/11/05 10:57am Now that was a turbo charged finish!! http://www.sharescene.com/html/emoticons/lmaosmiley.gif
  15. rene in geneva

    AAH

    In reply to: africanus on Thursday 06/10/05 12:08pm Still got mine.I just keep adding to them as we go along. I still remember the phone call from the broker in early 02....Those were the days!! Thought at the time nah, don't sell as this is only the beginning. Thankfully it wasn't the beginning of the end, but it has been close! http://www.sharescene.com/html/emoticons/wacko.gif
  16. whoo hoo!! 656 http://www.sharescene.com/html/emoticons/lmaosmiley.gif
  17. more good news........ http://www.presseportal.de/story.htx?nr=718300&ressort=7 http://www.sharescene.com/html/emoticons/graduated.gif
  18. Xstrata news conference in London today. Will they mention the mighty Ox? http://www.sharescene.com/html/emoticons/unsure.gif http://www.xstrata.com/investors.php?id=presentation
  19. rene in geneva

    AAH

    In reply to: fastenyourseatbelt on Friday 10/06/05 08:10pm I think they must have folded in disgust http://www.sharescene.com/html/emoticons/sad.gif
  20. rene in geneva

    AAH

    Houston, do we have lift off?! http://www.sharescene.com/html/emoticons/lmaosmiley.gif
  21. rene in geneva

    AAH

    In reply to: peppy on Tuesday 17/05/05 12:10am The volitality is magnified on this stock by two main factors: 1/Traders love it, and 2/ Margin lending accelerates the trend both ways. I'll go on record and say that Mel is a good leader for this company, and I hope he stays. Maybe they should do a Pacific Hydro and throw the books open to JNJ, Merck and others. But then again the problem of the settlement amount and the ongoing royalty arrangement would probably make due diligence unworkable. CSL was crunched as well today, so it isn't just dear old peppy. http://www.sharescene.com/html/emoticons/lmaosmiley.gif
  22. rene in geneva

    AAH

    What an arm wrestle today; the forces of good and evil in mortal combat. http://www.sharescene.com/html/emoticons/puke.gif Pity it's with my money!!
  23. rene in geneva

    AAH

    In reply to: theadder on Monday 09/05/05 08:15pm With this SP they might be taken over by Domantis! http://www.sharescene.com/html/emoticons/blink.gif
  24. rene in geneva

    AAH

    In reply to: Krapov on Saturday 07/05/05 07:26pm Hi Krapov, doesn't this recent announcment somewhat contradict your assertion that PTD does not have any IP that is uniquely theirs? http://www.peptech.com/peptech/content/ass...0success(1).pdf cheers, Rene
  25. rene in geneva

    AAH

    Wolve, I think you are giving the market too much credit for being an impartial and unemotional arbiter of the value of securities. If that were the case, over optimistic valuations would never occur. I think what we have here is a good (fantastic http://www.sharescene.com/html/emoticons/smile.gif) stock in an unloved sector. A stock that is too volatile for many investors to properly assess. This situation will change, and when it does it will remind us of the rapid change in sentiment we have just experienced in the resource sector.
×
×
  • Create New...